First Time Loading...

Destiny Pharma PLC
LSE:DEST

Watchlist Manager
Destiny Pharma PLC Logo
Destiny Pharma PLC
LSE:DEST
Watchlist
Price: 19.25 GBX 5.48% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

DEST's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. [ Read More ]

The intrinsic value of one DEST stock under the Base Case scenario is 5.06 GBX. Compared to the current market price of 19.25 GBX, Destiny Pharma PLC is Overvalued by 74%.

Key Points:
DEST Intrinsic Value
Base Case
5.06 GBX
Overvaluation 74%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Destiny Pharma PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DEST stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Destiny Pharma PLC

Provide an overview of the primary business activities
of Destiny Pharma PLC.

What unique competitive advantages
does Destiny Pharma PLC hold over its rivals?

What risks and challenges
does Destiny Pharma PLC face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Destiny Pharma PLC.

Provide P/S
for Destiny Pharma PLC.

Provide P/E
for Destiny Pharma PLC.

Provide P/OCF
for Destiny Pharma PLC.

Provide P/FCFE
for Destiny Pharma PLC.

Provide P/B
for Destiny Pharma PLC.

Provide EV/S
for Destiny Pharma PLC.

Provide EV/GP
for Destiny Pharma PLC.

Provide EV/EBITDA
for Destiny Pharma PLC.

Provide EV/EBIT
for Destiny Pharma PLC.

Provide EV/OCF
for Destiny Pharma PLC.

Provide EV/FCFF
for Destiny Pharma PLC.

Provide EV/IC
for Destiny Pharma PLC.

Show me price targets
for Destiny Pharma PLC made by professional analysts.

What are the Revenue projections
for Destiny Pharma PLC?

How accurate were the past Revenue estimates
for Destiny Pharma PLC?

What are the Net Income projections
for Destiny Pharma PLC?

How accurate were the past Net Income estimates
for Destiny Pharma PLC?

What are the EPS projections
for Destiny Pharma PLC?

How accurate were the past EPS estimates
for Destiny Pharma PLC?

What are the EBIT projections
for Destiny Pharma PLC?

How accurate were the past EBIT estimates
for Destiny Pharma PLC?

Compare the revenue forecasts
for Destiny Pharma PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Destiny Pharma PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Destiny Pharma PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Destiny Pharma PLC compared to its peers.

Compare the P/E ratios
of Destiny Pharma PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Destiny Pharma PLC with its peers.

Analyze the financial leverage
of Destiny Pharma PLC compared to its main competitors.

Show all profitability ratios
for Destiny Pharma PLC.

Provide ROE
for Destiny Pharma PLC.

Provide ROA
for Destiny Pharma PLC.

Provide ROIC
for Destiny Pharma PLC.

Provide ROCE
for Destiny Pharma PLC.

Provide Gross Margin
for Destiny Pharma PLC.

Provide Operating Margin
for Destiny Pharma PLC.

Provide Net Margin
for Destiny Pharma PLC.

Provide FCF Margin
for Destiny Pharma PLC.

Show all solvency ratios
for Destiny Pharma PLC.

Provide D/E Ratio
for Destiny Pharma PLC.

Provide D/A Ratio
for Destiny Pharma PLC.

Provide Interest Coverage Ratio
for Destiny Pharma PLC.

Provide Altman Z-Score Ratio
for Destiny Pharma PLC.

Provide Quick Ratio
for Destiny Pharma PLC.

Provide Current Ratio
for Destiny Pharma PLC.

Provide Cash Ratio
for Destiny Pharma PLC.

What is the historical Revenue growth
over the last 5 years for Destiny Pharma PLC?

What is the historical Net Income growth
over the last 5 years for Destiny Pharma PLC?

What is the current Free Cash Flow
of Destiny Pharma PLC?

Financials

Balance Sheet Decomposition
Destiny Pharma PLC

Current Assets 10.7m
Cash & Short-Term Investments 9.8m
Receivables 663.1k
Other Current Assets 176.8k
Non-Current Assets 2.4m
PP&E 21.6k
Intangibles 2.3m
Current Liabilities 1.1m
Accounts Payable 1.1m
Efficiency

Earnings Waterfall
Destiny Pharma PLC

Revenue
0 GBP
Operating Expenses
-7.2m GBP
Operating Income
-7.2m GBP
Other Expenses
1.2m GBP
Net Income
-6m GBP

Free Cash Flow Analysis
Destiny Pharma PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DEST Profitability Score
Profitability Due Diligence

Destiny Pharma PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Destiny Pharma PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

DEST Solvency Score
Solvency Due Diligence

Destiny Pharma PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Destiny Pharma PLC's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DEST Price Targets Summary
Destiny Pharma PLC

Wall Street analysts forecast DEST stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DEST is 62.22 GBX with a low forecast of 61.61 GBX and a high forecast of 64.05 GBX.

Lowest
Price Target
61.61 GBX
220% Upside
Average
Price Target
62.22 GBX
223% Upside
Highest
Price Target
64.05 GBX
233% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

DEST Price
Destiny Pharma PLC

1M 1M
-39%
6M 6M
-66%
1Y 1Y
-39%
3Y 3Y
-88%
5Y 5Y
-76%
10Y 10Y
-91%
Annual Price Range
19.25
52w Low
17.5
52w High
82
Price Metrics
Average Annual Return 4.32%
Standard Deviation of Annual Returns 59.63%
Max Drawdown -91%
Shares Statistics
Market Capitalization 18.3m GBX
Shares Outstanding 95 311 900
Percentage of Shares Shorted
N/A

DEST Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Destiny Pharma PLC Logo
Destiny Pharma PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

18.3m GBP

Dividend Yield

0%

Description

Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. The company is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The firm is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.

Contact

SUSSEX
BRIGHTON
Sussex Innovation Centre, Science Park Square, Falmer
+441273704440.0
https://www.destinypharma.com/

IPO

2017-09-04

Employees

14

Officers

Founder, Chief Scientific Officer & Director
Dr. William Guy Love
CFO, Company Secretary & Director
Mr. Shaun Claydon ACA
Interim CMO & Senior Independent Director
Dr. Debra Barker M.D., MSc.
CEO & Director
Mr. Christopher John Tovey BSc

See Also

Discover More
What is the Intrinsic Value of one DEST stock?

The intrinsic value of one DEST stock under the Base Case scenario is 5.06 GBX.

Is DEST stock undervalued or overvalued?

Compared to the current market price of 19.25 GBX, Destiny Pharma PLC is Overvalued by 74%.